Physician profile
Thomas Christopher Morris
NPI 1689666380
$4,815.47
in general payments reported to CMS, 2019-2025
34 companies · $1,474 in 2025
The $1,474 reported for 2025 was more than what 87% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2022: $305 · 2023: $1,670 · 2024: $1,254 · 2025: $1,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,399.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $575.78 | 2023-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $509.18 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $470.93 | 2023-2025 | Myfembree |
| Novo Nordisk INC | $460.05 | 2022-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $416.37 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $388.18 | 2022-2025 | Bijuva |
| Pfizer INC. | $218.09 | 2022-2025 | |
| Amgen INC. | $180.99 | 2022-2024 | Evenity, Prolia |
| Cosette Pharmaceuticals INC. | $176.71 | 2025 | Vyleesi |
| Gynesonics, INC. | $147.20 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Organon LLC | $138.49 | 2022-2025 | Nexplanon |
| Lilly USA, LLC | $138.00 | 2023-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $132.75 | 2023-2024 | Cologuard Collection Kit |
| Myriad Women'S Health, INC. | $130.82 | 2023 | Myrisk |
| Hologic Sales and Service, LLC | $116.11 | 2023-2025 | Thinprep 2000 Processor, Aptima, Myosure Tissue Removal Device |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $111.29 | 2019 | |
| Exeltis, USA INC. | $64.02 | 2023-2025 | Slynd |
| Idorsia Pharmaceuticals US INC | $62.01 | 2023-2024 | Quviviq |
| Vivus LLC | $52.74 | 2024-2025 | Pancreaze, Qsymia |
| Coopersurgical, INC. | $42.32 | 2023-2024 | Paragard T 380a, Paragard T 380a |
| Millicent US INC | $39.58 | 2025 | Intrarosa, Femlyv, Femring |
| Shield Therapeutics INC | $32.87 | 2023-2024 | Accrufer |
| Mycovia Pharmaceuticals, INC. | $25.10 | 2023 | Vivjoa |
| Evofem Biosciences, INC. | $21.94 | 2025 | Phexxi, Solosec, Phexx |
| Minerva Surgical, INC | $20.63 | 2022 | |
| Medtronic, INC. | $19.89 | 2023 | Ligasure |
| Abbott Laboratories | $19.81 | 2025 | Alinity M |
| Janssen Pharmaceuticals, INC | $17.68 | 2023 | Spravato |
| Scynexis, INC. | $15.80 | 2022 | |
| Mylan Pharmaceuticals INC. | $15.24 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.94 | 2022 | |
| Becton, Dickinson and Company | $14.80 | 2023 | Bd Onclarity |
| Aspira Women'S Health INC | $13.80 | 2023 | Ova1 |
| Vbi Vaccine (Delaware) INC. | $11.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.